| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Lunai Bioworks Inc.$2.46
+0.07 (+2.93%)
Market Cap
10.25 M
EPS
-61.29
P/E Ratio
-
Value Trade
94.37 K
SEC Financials
Q1 2026Dilution Risk
Revenue
20.94 K
R&D Expenses
15.95 K
Total Assets
9.86 M
Total Liabilities
19.41 M
Equity
-9.55 M
4.63 %
Week
-11.22 %
1 Month
-51.03 %
3 Month
-79.38 %
6 Month
-99.27 %
5 Year
-99.53 %
All Time
Cash Data
Cash Position
3.16 M
Monthly Burn
492.00 K
Runway
4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
171.37 K
52 Week Range
1.21 - 35.97
% held by Insiders
44.4 %
% held by Institutions
2.7 %
Enterprise Value
8.50 M
Total Shares
36.27 M
Short %
0.49 %
Float Shares
24.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lunai Bioworks Inc.
87Total events
2Upcoming
24Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 2
TBD
T1FDA Approval
Subscribe to view catalyst details
TBD
T3Development Candidate Nomination
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LNAI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LNAI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-10-16 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LNAI▲ +2.9%today
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
Lunai Bioworks has filed an amended complaint in Delaware against ten defendants for alleged naked short selling, claiming over 81% of its shares faced delivery failures. The complaint highlights instances of excessive trading volume and seeks treble damages under federal law. Lunai's leadership emphasizes accountability and ongoing investigations into trading activities.
Read more →LNAI▲ +40.6%on this news
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
Lunai Bioworks has made significant strides in establishing itself as a leader in biotechnology, particularly in biodefense and precision neurology. The company secured a multi-year defense contract and formed the Pathfinder Consortium with prestigious institutions. Additionally, it is actively addressing market manipulation through legal action to protect shareholder value. The CEO emphasizes the company's commitment to advancing its platforms and creating long-term value.
Read more →LNAI▲ +40.6%on this newsshared move
LUNAI BIOWORKS
Lunai Bioworks has made significant strides by securing a revenue-generating defense contract with the U.S. government and advancing its precision neurology pipeline through various collaborations. The company formed the Pathfinder Consortium to enhance its biodefense capabilities and received funding for research initiatives in neurological diseases. Lunai has taken legal action against market manipulation that may have affected its stock price, emphasizing its commitment to shareholder value. The company aims to expand its platforms and validate its technology in both drug development and national security.
Read more →LNAI▲ +16%on this news
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
Lunai Bioworks and BrainStorm Therapeutics have announced a strategic collaboration to discover and advance novel therapeutic targets for neurological diseases, supported by a grant from the LouLou Foundation. The partnership combines AI-driven discovery with human-derived organoid systems, aiming to improve translational success and address unmet medical needs in conditions like Parkinson's disease and rare genetic epilepsies. Initial efforts will focus on identifying biomarkers and developing high-confidence therapeutic programs for pharmaceutical partnering.
Read more →LNAIFederal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
A U.S. District Court has allowed Lunai Bioworks to expedite discovery to identify 'John Doe' naked short sellers. This decision follows allegations of market manipulation affecting Lunai's stock price. The company aims to hold these sellers accountable for damages. Lunai's legal team plans to pursue further action based on the findings from this discovery.
Read more →LNAI▼ -10.2%on this newsshared move
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
Lunai Bioworks, Inc. has announced a reverse stock split at a ratio of 1-for-8, effective May 22, 2026. This action, approved by stockholders, aims to boost the share price to meet Nasdaq listing requirements. The company previously conducted a 1-for-10 reverse stock split in September 2025. The split will reduce the number of outstanding shares significantly.
Read more →LNAILunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP
Lunai Bioworks has completed a $20 million preferred equity issuance to acquire CNS delivery and neurotherapeutic intellectual property. This acquisition aims to enhance their capabilities in treating neurological diseases, particularly Alzheimer's, by integrating novel delivery technologies. The company anticipates improved drug development efficiency and potential partnerships, though it faces compliance scrutiny from Nasdaq.
Read more →LNAI▲ +10.1%on this news
Lunai Bioworks, Inc. Announces Postponement of Special Meeting of Stockholders to
Lunai Bioworks, Inc. has announced the postponement of its Special Meeting of Stockholders from May 4, 2026, to May 8, 2026. The delay is intended to provide stockholders additional time to vote and help the company secure a quorum. The Special Meeting will be conducted virtually to facilitate participation. This change was prompted by delays in the distribution of proxy materials affecting broker discretionary voting. Stockholders are encouraged to submit their proxies by the deadline to ensure their votes are cast.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships
Lunai Bioworks and Geneial have signed a Letter of Intent to collaborate on building patient cohorts for rare neurological disorders. This partnership aims to convert fragmented patient data into actionable insights for drug development, addressing a significant bottleneck in the industry. Initial programs will integrate datasets from multiple registries to support clinical development and therapeutic programs.
Read more →LNAI▲ +39.8%on this news
Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion
Lunai Bioworks has announced a revenue-generating collaboration through its subsidiary BioSymetrics, focusing on AI-enabled chemical threat assessment. This multi-year partnership aims to enhance the identification and understanding of neuroactive compounds. The collaboration reflects Lunai's commitment to advancing dual-use technologies in defense and pharmaceutical applications.
Read more →LNAI▲ +22.9%on this news
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications
Lunai Bioworks has announced a $20 million acquisition of blood-brain barrier delivery technology from the Clemann Group. This strategic move aims to enhance its Alzheimer's drug pipeline by improving the delivery of therapeutics to the brain. The fixed conversion price structure strengthens Lunai's equity position while maintaining compliance with NASDAQ regulations. CEO David Weinstein highlighted the acquisition's potential to revolutionize treatment for Alzheimer's and other CNS diseases.
Read more →LNAI▲ +22.9%on this news
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Sacramento, CA
Lunai Bioworks has announced a strategic transaction to acquire blood-brain barrier delivery technology and CNS Alzheimer's drug assets from the Clemann Group for $20 million. This acquisition, structured as Series B Convertible Preferred stock at a fixed conversion price of $1.50 per share, enhances Lunai's pipeline by improving therapeutic delivery to the brain. The new platform is expected to overcome a significant barrier to CNS drug development, allowing for better targeting and activation of therapies specifically in the brain. CEO David Weinstein highlighted the transaction as a transformative step in the company’s capabilities.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model
Lunai Bioworks has launched the Pathfinder Consortium to enhance U.S. chemical defense capabilities against emerging threats. This initiative aims to consolidate fragmented resources into a unified framework, allowing for rapid antidote development within approximately three years. The consortium leverages AI technology and collaboration with leading experts to streamline the process of creating effective countermeasures.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company advancing precision therapeutics in central nervous system (CNS) disorders...
Lunai Bioworks has secured U.S. Patent No. 12,369,861, which focuses on methods for debiasing data in drug discovery. This foundational patent is crucial for their AI-driven platform, enhancing multimodal data standardization and disease stratification. CEO David Weinstein emphasized that this patent is vital for improving biomarker discovery and supports their long-term strategy in precision therapeutics.
Read more →LNAI▼ -10.2%on this news· ran to -29% by day 3shared move
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein...
Lunai Bioworks (NASDAQ: LNAI) was featured on CNBC's Business Minute, where CEO David Weinstein discussed the company's AI-driven approach to drug discovery and biodefense. The platform aims to enhance therapeutic development for CNS diseases and improve biodefense preparedness by integrating advanced machine learning and biological datasets. The segment reflects increasing investor interest in AI technologies for healthcare and national security.
Read more →LNAI▲ +24.7%on this news· ran to +60% by day 1
Lunai Bioworks, Inc. Issues Letter to Shareholders Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several...
Lunai Bioworks, Inc. has completed its AI platform, which is now commercial. The company is negotiating partnerships with pharmaceutical firms to enhance drug discovery processes. Lunai's approach aims to reduce drug development timelines and costs while increasing the probability of success. The company has established three revenue streams focused on AI drug discovery, biodefense, and immunotherapy.
Read more →LNAI▲ +24.7%on this news· ran to +60% by day 1
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a ...
Lunai Bioworks has initiated a collaboration to analyze data from a Phase 2 metastatic colorectal cancer trial using its AI platform. The goal is to identify patient subgroups that may benefit most from the therapy, optimizing trial design and inclusion criteria. This pilot project could expand into a broader program if successful, enhancing patient stratification in clinical trials.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Lunai Bioworks has launched a new drug discovery program targeting Alcohol Use Disorder (AUD) after achieving significant milestones in its NIH-supported AI initiative. The program aims to develop innovative therapies for a condition affecting around 30 million Americans, with most not receiving effective treatment. The initiative highlights the potential for precision medicine in addressing the complexities of AUD.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons As global attention intensifies around the dual-use risks of advanced artificial intelligence in chemistry and biology, Lunai Bioworks (NASDAQ: LNAI) ...
Lunai Bioworks has launched Sentinel, an AI safeguard designed to prevent the generation of novel chemical agents. This transformer-based biosecurity layer integrates directly into AI systems, utilizing proprietary datasets to detect hazardous molecular designs in real time. The initiative addresses growing concerns over the dual-use risks of AI in chemistry and biology, positioning Lunai at the forefront of AI safety.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under ...
Lunai Bioworks has launched a new drug discovery program targeting Alcohol Use Disorder (AUD) after achieving significant milestones in its NIH-funded AI initiative. The program aims to develop innovative therapies for AUD, which affects around 30 million Americans, with most receiving no effective treatment. The initiative is supported by a STTR grant and aims to address the unmet medical needs in this area.
Read more →LNAILunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance Lunai Bioworks Inc. (NASDAQ: LNAI), an AI-driven pharmaceutical discovery company, was featured in International Business Times in a year-end...
Lunai Bioworks Inc. is highlighted in International Business Times for its strategic positioning and active partnership discussions in the CNS sector. The company is negotiating with pharmaceutical firms on programs targeting diseases like Parkinson's and Alzheimer's. Amid a challenging market, Lunai's Augusta platform is recognized for its innovative approach to drug discovery, addressing unmet needs in CNS disorders.
Read more →LNAI▼ -8.7%on this news· ran to -22% by day 3
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three...
Lunai Bioworks has identified three subtypes of Parkinson's disease, which may enhance therapeutic development and strategic partnerships. Utilizing its Augusta Platform, the company integrated extensive proteomic data to uncover these subtypes linked to disease progression. This advancement aims to improve trial success rates and reduce development timelines in a growing market.
Read more →LNAI▼ -15%on this news
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, today announced it has secured its first Letter of Intent (LOI)...
Lunai Bioworks has secured its first Letter of Intent to license its immune cell therapy, which has shown complete regression of pancreatic tumors in humanized preclinical models. This milestone follows a peer-reviewed publication and a successful pre-IND meeting with the FDA. The company plans to initiate a Phase I clinical trial for its Dendritic Cell Combination Therapy targeting high-need solid tumors.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen Durchbruch in der allogenen Krebsimmuntherapie bedeutet Lunai Bioworks (NASDAQ: LNAI), ein KI-gestütztes Unternehmen für Arzneimittelforschung und Bioabwehr, hat einen wichtigen wissenschaftlichen...
Lunai Bioworks has announced a significant breakthrough in cancer immunotherapy, achieving complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. This was made possible through their second-generation dendritic cell therapy platform, which utilizes genetically modified dendritic cells to activate the body's immune system against cancer. The findings were published in the journal 'Vaccines' and are expected to advance ongoing partnership discussions for the therapy.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks、前臨床のヒト化モデルにおいて、原発および転移性膵臓がんの完全退縮を達成──オールロジェニックがん免疫療法における画期的なブレークスルーを示す AIを活用した創薬およびバイオディフェンス企業である Lunai Bioworks（NASDAQ: LNAI）は、主要な科学的ブレークスルーを発表した。同社の次世代免疫細胞療法により、ヒト化マウスモデルにおいて原発および転移性の膵臓腫瘍が完全退縮したことが確認された。...
Lunai Bioworks has announced significant advancements in its vaccine development, achieving complete remission in a study involving second-generation dendritic cell therapies. The research, published in the journal 'Vaccines', emphasizes the company's innovative use of AI in enhancing treatment efficacy. CEO David Weinstein highlighted the importance of these findings for future clinical applications.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks réussit à éliminer complètement les tumeurs pancréatiques primaires et secondaires dans des modèles humanisés précliniques, marquant une avancée significative pour l'immunothérapie allogénique contre le cancer Lunai Bioworks (NASDAQ : LNAI), une entreprise spécialisée dans la découverte de médicaments et la défense biologique utilisant l'intelligence...
Lunai Bioworks has announced a significant breakthrough in cancer immunotherapy, achieving complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. This advancement, published in the journal 'Vaccines', details a second-generation dendritic cell therapy that enhances immune response against cancer. The results pave the way for potential clinical applications and partnerships.
Read more →LNAI▼ -8.5%on this news
Lunai Bioworks logra la regresión completa de tumores pancreáticos primarios y metastásicos Lunai Bioworks (NASDAQ: LNAI), una empresa de descubrimiento de fármacos y biodefensa impulsada por IA ha anunciado un importante avance científico:...
Lunai Bioworks has reported a significant scientific breakthrough with its second-generation dendritic cell therapy, achieving complete regression of primary and metastatic pancreatic tumors in humanized preclinical models. This advancement, published in the journal 'Vaccines', showcases the therapy's potential to activate the immune system against cancer. The findings support ongoing collaborations and clinical applications.
Read more →LNAI▼ -12.8%on this news· ran to -25% by day 3shared move
Lunai Bioworks 在臨床前人源化模型內，實現原發性和轉移性胰臟腫瘤的完全消退，標誌為同種異體癌症免疫療法的突破 Lunai Bioworks（納斯達克股票交易所代號：LNAI）是利用人工智能驅動藥物研發與生物防禦的公司，宣佈重大科學突破：該公司的新一代免疫細胞療法在人源化小鼠模型中，導致原發性和轉移性胰臟腫瘤完全消退。 2025 年 11 月 2...
Lunai Bioworks has announced the development of a new generation of cancer therapies utilizing modified dendritic cells. Their approach aims to enhance tumor-inhibitory functions and potentially lead to tumor regression. The company is leveraging artificial intelligence to innovate in drug development, marking a significant step forward in cancer treatment.
Read more →LNAI▼ -12.8%on this news· ran to -25% by day 3shared move
Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefense company, has announced a major scientific breakthrough: its...
Lunai Bioworks has reported a significant breakthrough in cancer immunotherapy, achieving complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. This advancement stems from their second-generation dendritic cell therapy, which utilizes genetically enhanced immune cells. The findings, published in the journal 'Vaccines', are crucial for future clinical applications and partnerships.
Read more →LNAILunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lunai Bioworks, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price at or above $1.00 for 11 consecutive business days. This compliance enables the company to remain listed on The Nasdaq Capital Market. CEO David Weinstein highlighted this achievement as a testament to their strategic execution and a commitment to shareholder value amid a transformative period for the company. Lunai Bioworks is focused on enhancing its AI-driven capabilities in drug discovery and biodefense.
Read more →LNAIEXCHANGE AGREEMENT This EXCHANGE AGREEMENT (this " Agreement ") is entered into as of [ ], 2025 (the " Effective Date "), by and between Renovaro Inc., a Delaware corporation (the " Company "), and [ ] (the " Holder " an
Renovaro Inc. has entered into an exchange agreement with a Holder to replace secured promissory notes with unsecured convertible notes. This exchange is intended to address the immediate financial obligations associated with the current notes. The new replacement notes will have an increased principal amount and an extended maturity date. This move reflects the company's strategy to manage its debt structure, although it may involve increased financial risks.
Read more →LNAIRenovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, an
Renovaro and BioSymetrics have announced a definitive merger agreement aimed at advancing AI-driven biomarker discovery and precision medicine. The collaboration is set to integrate BioSymetrics' proprietary Elion platform, enhancing Renovaro's capabilities in oncology and drug discovery. This strategic combination is focused on expediting translational research and streamlining the development of effective therapeutics. The merger is expected to close in March 2025, pending regulatory approvals and customary closing conditions.
Read more →LNAIRenovaro to Acquire Predictive Oncology in All-Stock Transaction Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of long
Renovaro Inc. has announced its intention to acquire Predictive Oncology in an all-stock transaction, allowing access to a biobank of over 150,000 tumor specimens and extensive drug response data. This acquisition aims to enhance Renovaro's AI-driven platforms for cancer diagnostics and drug discovery. The combined resources, including Predictive Oncology's multi-omic drug discovery platform, are expected to improve treatment outcomes by helping oncologists tailor therapies for individual patients. The deal reflects a strategic move to increase capabilities in personalized medicine and precision oncology.
Read more →LNAIRenovaro, Inc. Announces $10 million in Equity Committed Los Angeles
Renovaro, Inc. has announced the commitment of $10 million in additional equity, priced at $1.4726 per share, along with 10 percent warrant coverage. The company's CEO, Mark Dybul, highlighted investor confidence and indicated that this investment could be a stepping stone towards securing more substantial financing from various institutions. Renovaro is open to exploring different sources of funding that could total tens of millions of dollars, thereby enhancing its strategic financial positioning.
Read more →LNAIRenovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy Los Angeles, USA and Amsterdam, Netherlands
Renovaro Inc. and Amsterdam UMC Cancer Center have entered into a Memorandum of Understanding to establish a joint company that will focus on developing personalized cancer immunotherapy. The collaboration intends to combine Renovaro's proprietary vaccine technology with the Cancer Center's immunomodulatory expertise to enhance cancer treatment. This new venture will be headquartered in Amsterdam and aims to innovate cancer therapies while improving patient outcomes. Both parties emphasize the need for thorough due diligence before advancing with the project.
Read more →LNAIRenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership Los Angeles and Amsterdam
RenovaroCube has announced its acquisition of 100% ownership of Cyclomics, enhancing their partnership in advanced cancer diagnostics. This move aims to leverage their combined technologies, including Cyclomics' innovative molecular biology techniques and RenovaroCube's AI-driven approach. The collaboration, backed by their relationships with Oxford Nanopore and Nvidia, positions them as leaders in cancer detection and treatment monitoring. This acquisition is expected to significantly improve early detection and personalized treatment for cancer patients.
Read more →LNAIAI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine Los Angeles
Renovaro Inc. has successfully acquired GEDi Cube Intl Ltd., merging AI health technology with advanced cell and gene therapy. This strategic combination aims to accelerate the development of personalized medicine and improve cancer detection and treatment methodologies. Under this new organizational structure, leadership from both companies will work together to enhance collaboration and innovation. The acquisition is positioned as a significant milestone in redefining healthcare, although it carries inherent risks associated with forward-looking statements regarding efficacy and execution.
Read more →LNAIRenovaro Biosciences Announces Results of Special Meeting of Shareholders Los Angeles
Renovaro Biosciences Inc. has announced the results of its Special Meeting of Shareholders, held on January 25, 2024. During the meeting, all proposals put forward to shareholders were approved based on the necessary voting thresholds. This outcome reflects robust support from shareholders for the company's direction and initiatives in cell, gene, and immunotherapy developments. Further details will be made available in the Company's Form 8-K, to be filed with the SEC.
Read more →LNAIMessage from Renovaro Bioscience, Inc.'s CEO, The Hon. Mark Dybul, MD Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024
Renovaro Biosciences, under CEO Mark Dybul, has reported significant advancements towards integrating AI with biotechnology for cancer treatment. The company is preparing for a crucial shareholder meeting regarding its merger with GEDi Cube, which has bolstered its technology through partnerships with NVIDIA. Recent pre-clinical trials of their cancer vaccine RENB-DC11 show promising results, potentially leading to human studies by late 2024. The combined efforts aim to enhance early cancer diagnosis and therapeutic options while pursuing stringent operational protocols for clinical trials.
Read more →LNAIRenovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors Los Angeles
Renovaro Biosciences has appointed Leni Boeren and Ruud Hendriks to its Board of Directors, bringing extensive financial expertise. This leadership change coincides with Renovaro's planned merger with GEDi Cube, which will rebrand as Renovaro AI. The partnership aims to leverage AI technology to innovate cancer therapies. However, the company faces challenges such as the need for shareholder approval and the complexities of merging two organizations.
Read more →LNAIAI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine Message from Renovaro Biosciences CEO, The Hon. Mark Dybul
Renovaro Biosciences has signed a definitive agreement to combine with GEDiCube, a company specializing in AI technology for early cancer detection. The new entity aims to leverage GEDiCube's proprietary AI platform alongside Renovaro's immunotherapy pipeline to enhance precision medicine capabilities. With the combined expertise of both companies, including a leadership team with significant industry experience, they anticipate launching commercial products in 2024. The merger is designed to improve patient outcomes through advanced diagnostics and treatment's effectiveness.
Read more →LNAIRenovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biot
Renovaro Biosciences has entered into a definitive agreement to merge with GEDi Cube, an AI health company, which will make GEDi Cube a wholly-owned subsidiary. The merger is intended to accelerate advancements in precision medicine, particularly for cancers with poor prognoses, utilizing AI for improved diagnosis and therapeutic development. The combined company plans to launch AI-driven diagnostic products by 2024 and initiate Phase 1/2 human studies targeting pancreatic and other solid tumors. This strategic partnership aims to enhance both companies' capabilities in drug discovery and treatment methodologies.
Read more →LNAILetter of Intent
Enochian BioSciences Inc. has expressed interest in acquiring GEDi Cube Intl Ltd to integrate advanced AI technologies into its therapeutic research. The acquisition aims to enhance Enochian's capabilities in developing innovative treatments for diseases, including cancers with limited options. The parties involved are set to initiate due diligence and agree to maintain confidentiality during the transaction process. This strategic move could potentially lead to human studies starting by mid to late 2024.
Read more →LNAIENOCHIAN BIOSCIENCES INC. ANNOUNCES ADJOURNMENT OF 2023
Enochian BioSciences Inc. announced the adjournment of its 2023 Annual Stockholder Meeting due to a lack of required quorum. The meeting, initially scheduled for June 22, 2023, will reconvene on July 21, 2023, giving stockholders additional time to vote on proposals. During this period, the company is soliciting votes and has engaged a proxy solicitor to aid in achieving quorum. All stockholders of record from May 10, 2023, are eligible to vote.
Read more →LNAIEnochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
Enochian BioSciences Inc. has announced that it remains on schedule to submit an Investigational New Drug Application for its cancer platform in early to mid-2024, following a positive review from the FDA on its Pre-IND submission. The platform utilizes a novel cell- and gene-therapy approach that has shown efficacy in mouse models, particularly for solid tumors like pancreatic cancer. Initial studies indicated an 80-90% reduction in tumor sizes, with hopeful results of significant immune cell infiltration. The company expresses optimism for beginning clinical trials in the first half of 2024.
Read more →LNAIEnochian BioSciences' CEO Letter to Shareholders Turning the Page; A Promising Future Los Angeles
Enochian BioSciences has reported promising data from independent studies on its novel cell-gene-immunotherapy, particularly for pancreatic cancer, showing significant tumor volume reduction. The company announced plans to accelerate its Pre-IND submission to the US FDA in light of these results, with potential clinical trials expected to begin in early 2024. The CEO expressed confidence in leveraging their research platform for additional therapeutic areas, including other solid tumors and chronic infectious diseases. Recent fundraising efforts have positioned the company strongly to maximize shareholder value as it pushes forward with its initiatives.
Read more →LNAIEnochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
Enochian BioSciences has announced promising proof-of-concept studies conducted by Dr. Anahid Jewett, showing significant tumor reductions in pancreatic cancer via their proprietary approach. Presented at the Annual Innate Killer Summit, the studies demonstrated strong immune responses and the potential to extend beyond pancreatic to other solid tumors. The company plans to submit a Pre-Investigational New Drug application to the FDA soon, with hopes of accelerated development for therapies addressing poor prognosis cancers.
Read more →LNAIEnochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
Enochian BioSciences has announced its achievement of full compliance with NASDAQ filing requirements. The company filed its Annual Report on Form 10-K on February 27, 2023, followed by Quarterly Reports for previous quarters in early March 2023. Leaders in the company expressed optimism regarding their ability to advance their technology aimed at treating solid tumors. This marks a significant step forward for the company after facing challenges.
Read more →LNAIEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended
Enochian BioSciences has received a notice from Nasdaq regarding the delayed filing of its Form 10-Q for the period ending December 31, 2022. This delay keeps the company in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely submission of financial reports. Although this notice does not immediately affect the company's listing status, failure to regain compliance within the specified 180 days could result in the delisting of the company’s stock. The company is working on a plan to address these compliance issues.
Read more →LNAIEnochian BioSciences Forges Ahead With Focused Approach, Promising Future
Enochian BioSciences Forges Ahead With Focused Approach, LOS ANGELES October 24, 2022 (NASDAQ: ENOB)-Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world's deadliest diseases. Last week, the Com
Read more →LNAIEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-K LOS ANGELES October 21, 2022 (NASDAQ: ENOB)- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Sto
Read more →LNAICEO's Letter to Shareholders 06/01/2022 (Updated 09/23/2022) Dear Shareholders: I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundatio
CEO's Letter to Shareholders 06/01/2022 (Updated 09/23/2022) I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundation is rooted in independently conducted science, and our commitment to the p
Read more →LNAIEnochian BioSciences Inc. (NASDAQ: ENOB)
Enochian BioSciences Inc. (NASDAQ: ENOB) CEO Letter to Shareholders After a rigorous review of internal data, Enochian Biosciences (the Company) is working aggressively to advance our HIV, cancer, and HBV pipelines towards potential studies in humans. The foundation of the Co
Read more →LNAIEnochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data
Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data LOS ANGELES July 01, 2022 (NASDAQ: ENOB)-In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors a c
Read more →LNAI01/2022 (Updated 06/06/2022) Dear Shareholders: I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundation is rooted in independently con
06/01/2022 (Updated 06/06/2022) I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundation is rooted in independently conducted science, and our commitment to the promise of our potential therap
Read more →LNAIDear Shareholders: I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundation is rooted in independently conducted science, and our commi
I have spoken to some of you about the serious and disturbing news that broke last week about Serhat Gumrukcu. Enochian's rigorous foundation is rooted in independently conducted science, and our commitment to the promise of our potential therapies remains strong. Enochian's va
Read more →LNAIScientific Leaders Agree on Promise of Enochian BioSciences Los Angeles
Scientific Leaders Agree on Promise of Enochian Los Angeles, May 31, 2022 (NASDAQ: ENOB) - Enochian BioSciences is working to solve our greatest public health threats like HIV, cancer, and coronavirus. The company's underlying scientific ideas are innovative with an elegant si
Read more →LNAIEnochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company - The Board learned of the Arrest of Dr. Serhat Gumruk u after the Press Relea
Enochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company Los Angeles, May 25, 2022 (NASDAQ: ENOB). The Board of Directors of Enochian BioSciences Inc. met today and expressed unanimous and str
Read more →LNAIEnochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience Los Angeles. April 20,2022. Enochian BioSciences (NASDAQ: ENOB). Enochian BioSci
Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience Los Angeles. April 20,2022. Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular a
Read more →LNAIEnochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years' Experience at Pfizer Los Angeles.
Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years' Experience at Pfizer Los Angeles. April 7, 2022. Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences, Inc., a company focused on gene-modified cellular and immunot
Read more →LNAIEnochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit
Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit LOS ANGELES, April 5, 2022, (NASDAQ: ENOB) - Enochian BioSciences, a company focused on gene-modified cellular and im
Read more →LNAIEnochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans
Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans LOS ANGELES, March 15, 2022. (NASDAQ: ENOB) Enochian BioSciences, a company focused on gene modified cellul
Read more →LNAIUPDATE Enochian BioSciences: At the Cutting Edge "The future of Biotech is disruptive science from unconventional sources" Dr. Mark Dybul, CEO To: Shareholders of Enochian BioSciences From: The Hon. Dr. Mark Dybul Subjec
Enochian BioSciences: At the Cutting Edge "The future of Biotech is disruptive science from unconventional sources" To: Shareholders of Enochian BioSciences From: The Hon. Dr. Mark Dybul Date: January 24, 2022 The past decades in technology, currencies (e.g., Blockchain an
Read more →LNAIDistinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants LOS ANGELES, August 30, 2021 (NASDAQ: ENOB) - Enochian BioSciences, a company focus
Read more →LNAIEnochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioScience's Scientific Approach
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer Dr. Dybul's Deep and Prestigious Scientific Helps to Affirm Enochian BioScience's Scientific LOS ANGELES, July 20, 2021 (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modifi
Read more →LNAIEnochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules LOS ANGELES, June 14, 2021 (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and c
Read more →LNAIEnochian Biosciences Elegant Simplicity: Integrating Diverse Scientific Approaches to Develop Cures Dr. Mark Dybul, Executive Vice Chairman March 9-10, 2021 HC Wainwright Global Life Sciences Conference NASDAQ: ENOB Forw
Enochian Biosciences Elegant Simplicity: Integrating Diverse Scientific Approaches to Develop Cures Dr. Mark Dybul, Executive Vice Chairman March 9-10, 2021 HC Wainwright Global Life Sciences Conference NASDAQ: ENOB Forward-Looking Statements 2 Statements in this presentation th
Read more →LNAISECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 to Section 13 or 15(d) of the Securities Exchange Act of 1934 of Report (Date of earliest event reported): September 15, 2020 (Exact name of registrant as specified in its charter) Delaware 000-54478 45-2559340 (Stat
Read more →LNAIEnochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraf
Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures Presentation - hhttp://www.enochianbio.com/wp-content/uploads/2020/05/Final-Poster-SyngeneicMouse_431_ASGCT_Poster_Final-05112020-2.pdf Presentation - hhttp://www.enochianbio.com/wp-content/uplo
Read more →LNAIWolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Don Weinberger (212) 370-4500, (212) 370-4505 fax
Axelrod Weinberger Associates, LLC D. Axelrod, CFA/Don Weinberger 370-4500, (212) 370-4505 fax BIOTECH USA INC. ANNOUNCES THE PURCHASE OF 5, 2016. New York, USA. DanDrit Biotech USA Inc. (OTCQB: DDRT) today announced that it has entered into an agreement to acquire privately
Read more →LNAIWolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Donald C. Weinberger (212) 370-4500, (212) 370-4505 fax steve@wolfeaxelrod.com , don@wolfeaxelrod.com DanDrit Biotech A/S Si
Wolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Donald C. Weinberger (212) 370-4500, (212) 370-4505 fax steve@wolfeaxelrod.com, don@wolfeaxelrod.com DanDrit Biotech A/S Signs Agreement to Commence Clinical Trials of MelCancerVac Copenhagen, Denmark, Septem
Read more →LNAIWolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Donald C. Weinberger (212) 370-4500, (212) 370-4505 fax steve@wolfeaxelrod.com , don@wolfeaxelrod.com DanDrit Biotech USA, I
Contact: For Immediate Release Wolfe Axelrod Weinberger Associates, LLC Stephen D. Axelrod, CFA/Donald C. Weinberger (212) 370-4500, (212) 370-4505 fax steve@wolfeaxelrod.com , don@wolfeaxelrod.com DanDrit Biotech USA, Inc. Signs Placement Agency Agreement with Sunrise Securiti
Read more →Competitive Position
How LNAI ranks across every disease it competes inCompetitive Position is a premium feature
See how LNAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial